Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
Liver, Cancer

About this trial
This is an interventional treatment trial for Liver focused on measuring Phase II, Hepatocellular carcinoma
Eligibility Criteria
Inclusion Criteria: Histologically proven diagnosis of hepatocellular or radiographic evidence of a hepatic lesion consistent with hepatoma and an alpha feto protein >500 ng/ ml The tumor is unresectable Performance status of < 2.0 > 18 years of age Informed consent to be signed by patient No previous treatment with thalidomide, alpha interferon, or octreotide The patient may have received previous chemotherapy either systemically or via the intra hepatic artery. The patient may have had previous surgery or regional therapy such as intra tumoral injection of alcohol, cryosurgery, or radiofrequency ablation. The patient must have measurable disease. If female, the patient must have a negative pregnancy test and agree not to fall pregnant during this therapy. Bilirubin <3 X ULN, AST/ALT<3 X ULN, creat<2, ANC>1.5, Platelet>75K Patients may not have symptomatic cholelithiasis. Exclusion Criteria:
Sites / Locations
- University of New Mexico
- New Mexico Cancer Care Associates
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Arm 1
Arm 2
Thalidomide+alpha interferon
Thalidomide+interferon+Octreotide